TEMERIT
-
Opinions on drugs -
Posted on
Oct 04 2006
- Updated on
Jan 14 2009
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the new indication
-
Clinical Benefit
Substantial |
The actual benefit is substantial. |
Clinical Added Value
moderate |
As a result, the Transparency Committee considers that NEBILOX brings about a moderate improvement in actual benefit (IAB III) in the handling of patients aged 70 and over who have mild to moderate stable chronic heart failure, with or without systolic dysfunction. |
Contact Us
Évaluation des médicaments